8 results on '"Hengjing Cui"'
Search Results
2. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells
- Author
-
Jinar Rostami, Maria Jäntti, Hengjing Cui, Maiju K. Rinne, Jyrki P. Kukkonen, Anna Falk, Anna Erlandsson, and Timo Myöhänen
- Subjects
Autophagy ,Alpha-synuclein ,Fibrils ,Propagation ,Calpain ,Synucleinopathies ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Growing evidence emphasizes insufficient clearance of pathological alpha-synuclein (αSYN) aggregates in the progression of Parkinson’s disease (PD). Consequently, cellular degradation pathways represent a potential therapeutic target. Prolyl oligopeptidase (PREP) is highly expressed in the brain and has been suggested to increase αSYN aggregation and negatively regulate the autophagy pathway. Inhibition of PREP with a small molecule inhibitor, KYP-2407, stimulates autophagy and reduces the oligomeric species of αSYN aggregates in PD mouse models. However, whether PREP inhibition has any effects on intracellular αSYN fibrils has not been studied before. In this study, the effect of KYP2407 on αSYN preformed fibrils (PFFs) was tested in SH-SY5Y cells and human astrocytes. Immunostaining analysis revealed that both cell types accumulated αSYN PFFs intracellularly but KYP-2047 decreased intracellular αSYN deposits only in SH-SY5Y cells, as astrocytes did not show any PREP activity. Western blot analysis confirmed the reduction of high molecular weight αSYN species in SH-SY5Y cell lysates, and secretion of αSYN from SH-SY5Y cells also decreased in the presence of KYP-2407. Accumulation of αSYN inside the SH-SY5Y cells resulted in an increase of the auto-lysosomal proteins p62 and LC3BII, as well as calpain 1 and 2, which have been shown to be associated with PD pathology. Notably, treatment with KYP-2407 significantly reduced p62 and LC3BII levels, indicating an increased autophagic flux, and calpain 1 and 2 levels returned to normal in the presence of KYP-2407. Our findings indicate that PREP inhibition can potentially be used as therapy to reduce the insoluble intracellular αSYN aggregates.
- Published
- 2020
- Full Text
- View/download PDF
3. Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon
- Author
-
Hengjing Cui, Joshua D. Elford, Okko Alitalo, Paula Perez-Pardo, Janne Tampio, Kristiina M. Huttunen, Aletta Kraneveld, Markus M. Forsberg, Timo T. Myöhänen, and Aaro J. Jalkanen
- Subjects
Aging ,General Neuroscience ,Neurology (clinical) ,Geriatrics and Gerontology ,Developmental Biology - Published
- 2023
4. A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy
- Author
-
Tony S. Eteläinen, M. Catarina Silva, Johanna K. Uhari-Väänänen, Francesca De Lorenzo, Maria H. Jäntti, Hengjing Cui, Marta Chavero-Pieres, Tommi Kilpeläinen, Christina Mechtler, Reinis Svarcbahs, Erin Seppälä, Juha R. Savinainen, Elena Puris, Gert Fricker, Mikko Gynther, Ulrika H. Julku, Henri J. Huttunen, Stephen J. Haggarty, and Timo T. Myöhänen
- Subjects
General Medicine - Abstract
Tauopathies are neurodegenerative diseases that are characterized by accumulation of hyperphosphorylated tau protein, higher-order aggregates, and tau filaments. Protein phosphatase 2A (PP2A) is a major tau dephosphorylating phosphatase, and a decrease in its activity has been demonstrated in tauopathies, including Alzheimer’s disease. Prolyl oligopeptidase is a serine protease that is associated with neurodegeneration, and its inhibition normalizes PP2A activity without toxicity under pathological conditions. Here, we assessed whether prolyl oligopeptidase inhibition could protect against tau-mediated toxicity in cellular models in vitro and in the PS19 transgenic mouse model of tauopathy carrying the human tau-P301S mutation. We show that inhibition of prolyl oligopeptidase with the inhibitor KYP-2047 reduced tau aggregation in tau-transfected HEK-293 cells and N2A cells as well as in human iPSC–derived neurons carrying either the P301L or tau-A152T mutation. Treatment with KYP-2047 resulted in increased PP2A activity and activation of autophagic flux in HEK-293 cells and N2A cells and in patient-derived iNeurons, as indicated by changes in autophagosome and autophagy receptor markers; this contributed to clearance of insoluble tau. Furthermore, treatment of PS19 transgenic mice for 1 month with KYP-2047 reduced tau burden in the brain and cerebrospinal fluid and slowed cognitive decline according to several behavioral tests. In addition, a reduction in an oxidative stress marker was seen in mouse brains after KYP-2047 treatment. This study suggests that inhibition of prolyl oligopeptidase could help to ameliorate tau-dependent neurodegeneration.
- Published
- 2023
5. Deletion or inhibition of prolyl oligopeptidase blocks lithium‐induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A
- Author
-
Hengjing Cui, Susanna Norrbacka, Freke Mertens, Timo T. Myöhänen, Faculty of Pharmacy, Divisions of Faculty of Pharmacy, Division of Pharmacology and Pharmacotherapy, Drug Research Program, Regenerative pharmacology group, and PREP in neurodegenerative disorders
- Subjects
Proline ,Lithium (medication) ,education ,Oligopeptidase ,Lithium ,Glycogen Synthase Kinase 3 beta/metabolism ,Toxicology ,Lithium/pharmacology ,Cell Line ,03 medical and health sciences ,chemistry.chemical_compound ,Okadaic Acid/pharmacology ,0302 clinical medicine ,Cell Line, Tumor ,Okadaic Acid ,Proto-Oncogene Proteins c-akt/metabolism ,medicine ,Humans ,Protein Phosphatase 2/antagonists & inhibitors ,Inositol ,Protein Phosphatase 2 ,Phosphorylation ,Protein kinase B ,GSK3B ,Proline/analogs & derivatives ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Tumor ,Glycogen Synthase Kinase 3 beta ,Chemistry ,Phosphorylation/drug effects ,Prolyl Oligopeptidases/antagonists & inhibitors ,General Medicine ,Protein phosphatase 2 ,Okadaic acid ,Molecular biology ,HEK293 Cells ,317 Pharmacy ,Prolyl Oligopeptidases ,Proto-Oncogene Proteins c-akt ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Alterations in prolyl oligopeptidase (PREP) activity have been connected, for example, with bipolar and major depressive disorder, and several studies have reported that lack or inhibition of PREP blocks the effects of lithium on inositol 1,4,5-triphosphate (IP3) levels. However, the impact of PREP modulation on other intracellular targets of lithium, such as glycogen synthase kinase 3 beta (GSK3b) or protein kinase B (Akt), has not been studied. We recently found that PREP regulates protein phosphatase 2A (PP2A), and because GSK3b and Akt are PP2A substrates, we studied if PREP-related lithium insensitivity is dependent on PP2A. To assess this, HEK-293 and SH-SY5Y cells with PREP deletion or PREP inhibition (KYP-2047) were exposed to lithium, and thereafter, the phosphorylation levels of GSK3b and Akt were measured by Western blot. As expected, PREP deletion and inhibition blocked the lithium-induced phosphorylation on GSK3b and Akt in both cell lines. When lithium exposure was combined with okadaic acid, a PP2A inhibitor, KYP-2047 did not have effect on lithium-induced GSK3b and Akt phosphorylation. Therefore, we conclude that PREP deletion or inhibition blocks the intracellular effects of lithium on GSK3b and Akt via PP2A activation.
- Published
- 2021
6. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy
- Author
-
Samuli Auno, Sampo Kurvonen, Poul Henning Jensen, Tommi Kilpeläinen, Lydia Zouzoula, Susanna Norrbacka, Hengjing Cui, Iiris Hovatta, Kalevi Trontti, Timo T. Myöhänen, Division of Pharmacology and Pharmacotherapy, PREP in neurodegenerative disorders, SLEEPWELL Research Program, Department of Psychology and Logopedics, Neuroscience Center, Mind and Matter, Iiris Hovatta / Principal Investigator, Genetics, Faculty of Pharmacy, Regenerative pharmacology group, Drug Research Program, and Divisions of Faculty of Pharmacy
- Subjects
alpha-synuclein ,multiple system atrophy ,TOXICITY ,DISEASE ,chemistry.chemical_compound ,0302 clinical medicine ,KYP‐2047 ,Phosphorylation ,PHOSPHORYLATION ,KYP-2047 ,0303 health sciences ,Neurodegeneration ,neurodegeneration ,PROTEIN PHOSPHATASE 2A ,MOUSE MODEL ,Transfection ,Cell biology ,Oligodendroglia ,medicine.anatomical_structure ,alpha‐synuclein ,317 Pharmacy ,PROLINE ,alpha-Synuclein ,Molecular Medicine ,AUTOPHAGY ,Original Article ,Cellular model ,Prolyl Oligopeptidases ,Cell Survival ,Nerve Tissue Proteins ,Protein Aggregation, Pathological ,Cell Line ,03 medical and health sciences ,Protein Aggregates ,SDG 3 - Good Health and Well-being ,medicine ,Humans ,Viability assay ,PARKINSONS ,030304 developmental biology ,Alpha-synuclein ,Synucleinopathies ,Autophagy ,synucleinopathies ,Cell Biology ,Original Articles ,DEGRADATION ,medicine.disease ,Oligodendrocyte ,chemistry ,prolyl oligopeptidase ,030217 neurology & neurosurgery - Abstract
Multiple system atrophy (MSA) is a fatal neurodegenerative disease where the histopathological hallmark is glial cytoplasmic inclusions in oligodendrocytes, rich of aggregated alpha-synuclein (aSyn). Therefore, therapies targeting aSyn aggregation and toxicity have been studied as a possible disease-modifying therapy for MSA. Our earlier studies show that inhibition of prolyl oligopeptidase (PREP) with KYP-2047 reduces aSyn aggregates in several models. Here, we tested the effects of KYP-2047 on a MSA cellular models, using rat OLN-AS7 and human MO3.13 oligodendrocyte cells. As translocation of p25α to cell cytosol has been identified as an inducer of aSyn aggregation in MSA models, the cells were transiently transfected with p25α. Similar to earlier studies, p25α increased aSyn phosphorylation and aggregation, and caused tubulin retraction and impaired autophagy in OLN-AS7 cells. In both cellular models, p25α transfection increased significantly aSyn mRNA levels and also increased the levels of inactive protein phosphatase 2A (PP2A). However, aSyn or p25α did not cause any cellular death in MO3.13 cells, questioning their use as a MSA model. Simultaneous administration of 10 µM KYP-2047 improved cell viability, decreased insoluble phosphorylated aSyn and normalized autophagy in OLN-AS7 cells but similar impact was not seen in MO3.13 cells.
- Published
- 2021
7. Corrigendum to 'Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells' [Biomed. Pharmacother. 131 (2020) 110788]
- Author
-
Anna Falk, Hengjing Cui, Maiju K. Rinne, Jinar Rostami, Maria Jäntti, Jyrki P. Kukkonen, Anna Erlandsson, and Timo T. Myöhänen
- Subjects
Pharmacology ,Alpha-synuclein ,Oligopeptidase ,General Medicine ,RM1-950 ,Fibril ,Cell biology ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,medicine ,Degradation (geology) ,Neuron ,Therapeutics. Pharmacology - Published
- 2021
8. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells
- Author
-
Anna Erlandsson, Hengjing Cui, Jyrki P. Kukkonen, Maiju K. Rinne, Jinar Rostami, Anna Falk, Maria Jäntti, Timo T. Myöhänen, PREP in neurodegenerative disorders, Division of Pharmacology and Pharmacotherapy, Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Department of Pharmacology, Medicum, Faculty of Pharmacy, Regenerative pharmacology group, and Divisions of Faculty of Pharmacy
- Subjects
0301 basic medicine ,Synucleinopathies ,Oligopeptidase ,ASTROCYTES ,chemistry.chemical_compound ,0302 clinical medicine ,PARKINSONS-DISEASE ,Propagation ,Cells, Cultured ,Neurons ,biology ,Calpain ,Neurodegeneration ,Parkinson Disease ,General Medicine ,LEWY BODIES ,3. Good health ,Cell biology ,317 Pharmacy ,030220 oncology & carcinogenesis ,Disease Progression ,ENDOPEPTIDASE ,Prolyl Oligopeptidases ,Intracellular ,Neurovetenskaper ,Serine Proteinase Inhibitors ,Proline ,RM1-950 ,Alpha-synuclein ,03 medical and health sciences ,Cell Line, Tumor ,medicine ,Autophagy ,Humans ,Secretion ,PROTEIN-LEVELS ,Pharmacology ,CLEAVAGE ,Neurosciences ,FILAMENTOUS INCLUSIONS ,medicine.disease ,PATHOLOGY ,030104 developmental biology ,chemistry ,biology.protein ,Fibrils ,Therapeutics. Pharmacology - Abstract
Corrigendum: Biomedicine & Pharmacotherapy 133 (2021) 111019 WOS:000604603600003 Growing evidence emphasizes insufficient clearance of pathological alpha-synuclein (alpha SYN) aggregates in the progression of Parkinson's disease (PD). Consequently, cellular degradation pathways represent a potential therapeutic target. Prolyl oligopeptidase (PREP) is highly expressed in the brain and has been suggested to increase alpha SYN aggregation and negatively regulate the autophagy pathway. Inhibition of PREP with a small molecule inhibitor, KYP-2407, stimulates autophagy and reduces the oligomeric species of alpha SYN aggregates in PD mouse models. However, whether PREP inhibition has any effects on intracellular alpha SYN fibrils has not been studied before. In this study, the effect of KYP2407 on alpha SYN preformed fibrils (PFFs) was tested in SH-SY5Y cells and human astmcytes. Immunostaining analysis revealed that both cell types accumulated alpha SYN PFFs intracellularly but KYP-2047 decreased intracellular alpha SYN deposits only in SH-SY5Y cells, as astrocytes did not show any PREP activity. Western blot analysis confirmed the reduction of high molecular weight alpha SYN species in SH-SY5Y cell lysates, and secretion of aSYN from SH-SY5Y cells also decreased in the presence of KYP-2407. Accumulation of alpha SYN inside the SH-SY5Y cells resulted in an increase of the auto-lysosomal proteins p62 and LC3BII, as well as calpain 1 and 2, which have been shown to be associated with PD pathology. Notably, treatment with KYP-2407 significantly reduced p62 and LC3BII levels, indicating an increased autophagic flux, and calpain 1 and 2 levels returned to normal in the presence of KYP-2407. Our findings indicate that PREP inhibition can potentially be used as therapy to reduce the insoluble intracellular alpha SYN aggregates.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.